EL7.AI
StocksMedium•16 November 2026•
1 min read

20/20 BioLabs OneTest Revenue Up 4.1% as Gross Margins Expand in Q3

Key Facts

1OneTest revenue increased 4.1% to $1.36 million for the first nine months of 2026.
2The company expanded gross margin to 32.8% with $3.63 million in cash and no outstanding debt as of September 30, 2026.
3Vermont executed a two-year firefighter cancer screening contract expected to contribute to Q4 revenue.

20/20 BioLabs reported that OneTest revenue increased 4.1% to $1.36 million for the first nine months of 2026. The company stated via GlobeNewswire that it expanded its gross margin to 32.8% while maintaining a cash position of $3.63 million and zero outstanding debt as of September 30, 2026.

The state of Vermont executed a two-year firefighter cancer screening contract with the company, which is expected to contribute to fourth-quarter revenue. AIDX closed at $0.2043 on November 13, 2026, having traded between a low of $0.19 and a high of $0.212 during that session.

Open on chart